The fight against HIV/AIDS is gaining significant momentum, fueled by advancements in treatment and prevention. According to a recent analysis by the Institute for Health Metrics and Evaluation, the Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry is expected to reach a staggering US$56.6 billion by 2033. This projected growth reflects a turning point in the battle against this disease.
Market Poised for Steady Growth:
The market is currently valued at a noteworthy US$34.83 billion in 2023 and is anticipated to maintain a steady trajectory with a Compound Annual Growth Rate (CAGR) of 6%. This ongoing expansion signifies the increasing availability and effectiveness of HIV-1 treatments, potentially leading to improved patient outcomes and a decline in disease burden.
The industry’s consistent expansion may be mainly ascribed to the ongoing increase in the prevalence of HIV-1 infections worldwide. Despite advancements in treatment options, approximately 37 million people globally are affected by the rising number of new cases. It’s interesting to note that the death rate linked to HIV-1 has not changed significantly over time, highlighting the urgency of
Currently, only half of the affected population has access to antiretroviral therapeutic interventions for disease management. This underscores a substantial gap in treatment accessibility that the healthcare industry aims to address over the forecasted decade.
Request a Sample of this Report Using a Work Email To Get a Quick Reply:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16202
Because of the large percentage of HIV patients in highly populous countries such as China and India, the Asia Pacific market is expected to become the fastest-growing market with the highest CAGR over the coming years. Furthermore, the massive amount of therapeutic interventions, as well as monetary support from corporate companies and medical companies, are anticipated to propel the industry forward.
Key Takeaways from the Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry Study
- North America led the 2022 market with a sales volume of US$ 21 Billion.
- According to a study conducted by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people had HIV at the end of 2018.
- Based on the World Health Organization (WHO), approximately 33.0 million people will be infected with HIV by 2021.
- Women and girls comprised 54% of all HIV-positive people, according to the WHO.
- From 2018 to 2022, sales increased significantly at a CAGR of 1.6%.
Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry Players
Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc., Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc., Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.
- In July 2021 – Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with the medical company Hetero Labs LTD to make darunavir plus ritonavir (DRV/r) available as a second-line treatment for HIV patients in low and middle-income countries for US$ 210 per patient/year.
- In March 2021, Gilead Sciences Inc. and Merck announced a collaboration agreement to co-develop and co-commercialize long-term HIV treatment. The investigational capsid inhibitor lenacapavir from Gilead and the investigational nucleoside reverse transcriptase translocation inhibitor islatravir from Merck will be paired to form a two-drug HIV regimen.
- On January 20, 2021 – HIV ViiV Healthcare evolved Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults.
Request for Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-16202
Key Segments Profiled in the Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry Survey
Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry by Drug Class:
- Nucleoside-Analog Reverse Transcriptase Inhibitor
- Non-Nucleoside Reverse Transcriptase Inhibitor
- Entry and Fusion Inhibitors
- Protease Inhibitors
- Integrase Inhibitors
- Coreceptor Antagonists
Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
